𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C

✍ Scribed by Venessa Pattullo; E. Jenny Heathcote; David K. H. Wong

Book ID
107593899
Publisher
Springer-Verlag
Year
2010
Tongue
English
Weight
296 KB
Volume
4
Category
Article
ISSN
1936-0533

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Merimepodib, pegylated interferon, and r
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 240 KB πŸ‘ 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a

Response to pegylated interferon alfa-2a
Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4
✍ Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 91 KB

## Abstract The safety and efficacy of pegylated interferon (PEG‐IFN) alfa‐2a and ribavirin were studied among patients treated for genotype 4 chronic hepatitis C. Ninety‐five patients with chronic hepatitis C genotype 4 were treated with PEG‐IFN alfa‐2a (180 ¡g/week) plus ribavirin (β‰₯11 mg/kg/day)